Combo Product Reforms Are A Priority For Next User Fee Round, FDA Officials Say
This article was originally published in The Gray Sheet
Executive Summary
Top FDA officials, including CDRH Director Jeffrey Shuren and FDA Deputy Commissioner Robert Califf, are sending strong signals that the designation and review processes for combination products are due for a significant reassessment. That should be a priority topic of upcoming user fee negotiations with industry, they say.
You may also be interested in...
Combo Products Won't Get Special Review Pathway At US FDA Anytime Soon
FDA's Jeffrey Shuren and Janet Woodcock tell a Senate committee that the agency is more concerned with implementing combination product provisions from the 21st Century Cures Act than working on a novel review pathway for device/drug combination products.
Reducing Waste In Combo Product Reviews: FDA Goes Lean
The agency disclosed plans to leverage "lean" management techniques, frequently employed in the private sector and by health care organizations, to streamline the process for reviewing new combination products.
Reducing Waste In Combo Product Reviews: FDA Goes Lean
The agency disclosed plans to leverage "lean" management techniques, frequently employed in the private sector and by health care organizations, to streamline the process for reviewing new combination products.